Incyte Corporation Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Jul 30 Calls Today's Calls

Call Details Incyte Corporation Earnings Conference Call (Q2 2009) Thu, Jul 30, 2009, 8:30 am Eastern Listen to the archived event audio About Incyte Corporation (NasdaqGM:INCY) Other Calls  Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes. The company’s products include INCB18424 (Oral), which is in Phase IIa clinical trials for the treatment of myelofibrosis, polycythemia vera/essential thrombocythemia, rheumatoid arthritis, refractory prostate cancer, and multiple myeloma; INCB18424 (Topical), which is in a Phase IIb clinical trial for the treatment of Psoriasis; and INCB28050, which is in Phase I trial for the treatment of rheumatoid arthritis. Its products also include INCB13739, which is in a Phase IIb clinical trial for the treatment of Type 2 Diabetes; and INCB20817, which is in a Phase I trial for the treatment of Type 2 Diabetes. In addition, the company’s products include INCB7839 in Phase IIa clinical trial for the treatment of solid tumors, and Phase II clinical trial for the treatment of breast cancer; INCB19602 in Phase IIa clinical trial for the treatment of Type 2 Diabetes; INCB8696 in Phase I clinical trial for the treatment of multiple sclerosis; INCB9471 in Phase II clinical trial for the treatment of HIV; and INCB15050 in Phase I clinical trial for the treatment of HIV. Further, its Investigational New Drug application cleared products include INCB28060 for the treatment of solid cancers and INCB24360 for the treatment of Oncology. The company operates in the United States, Canada, Germany, Sweden, and the United Kingdom. It has a collaborative research and license agreements with Pfizer, Inc. and ArtusLabs Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings